These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 23446443)

  • 21. Mild forms of toxic shock syndrome toxin-1-mediated exanthematous disease related to Staphylococcus aureus infection.
    Moriguchi N; Kano T; Yoshimatsu Y; Yanagida H
    J Infect Chemother; 2016 Aug; 22(8):571-3. PubMed ID: 26923257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Superantigen production by Staphylococcus aureus in psoriasis.
    Sayama K; Midorikawa K; Hanakawa Y; Sugai M; Hashimoto K
    Dermatology; 1998; 196(2):194-8. PubMed ID: 9568406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Staphylococcal scalded skin syndrome related to an exfoliative toxin A- and B-producing strain in preterm infants.
    Rieger-Fackeldey E; Plano LR; Kramer A; Schulze A
    Eur J Pediatr; 2002 Dec; 161(12):649-52. PubMed ID: 12447663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical manifestations of staphylococcal scalded-skin syndrome depend on serotypes of exfoliative toxins.
    Yamasaki O; Yamaguchi T; Sugai M; Chapuis-Cellier C; Arnaud F; Vandenesch F; Etienne J; Lina G
    J Clin Microbiol; 2005 Apr; 43(4):1890-3. PubMed ID: 15815014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exfoliative toxins of Staphylococcus aureus.
    Bukowski M; Wladyka B; Dubin G
    Toxins (Basel); 2010 May; 2(5):1148-65. PubMed ID: 22069631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis.
    Popa ER; Stegeman CA; Abdulahad WH; van der Meer B; Arends J; Manson WM; Bos NA; Kallenberg CG; Tervaert JW
    Rheumatology (Oxford); 2007 Jun; 46(6):1029-33. PubMed ID: 17409134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant Staphylococcus aureus exfoliative toxins are not bacterial superantigens.
    Plano LR; Gutman DM; Woischnik M; Collins CM
    Infect Immun; 2000 May; 68(5):3048-52. PubMed ID: 10769013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Animal studies of toxic shock syndrome.
    Quimby F; Nguyen HT
    Crit Rev Microbiol; 1985; 12(1):1-44. PubMed ID: 3160540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Occurrence of selected enterotoxins and toxic shock syndrome toxin genes among sensitive and resistant to methicillin Staphylococcus aureus isolated from clinical samples].
    Garbacz K; Dajnowska-Stanczewa A; Piechowicz L
    Med Dosw Mikrobiol; 2007; 59(3):201-6. PubMed ID: 18078114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxic shock syndrome: A dermatological emergency.
    Swarbrick AW; Kumarasinghe SP
    Australas J Dermatol; 2018 May; 59(2):154-155. PubMed ID: 28960233
    [No Abstract]   [Full Text] [Related]  

  • 31. Molecular typing of Staphylococcus aureus isolated from bovine mastitic milk on the basis of toxin genes and coagulase gene polymorphisms.
    Katsuda K; Hata E; Kobayashi H; Kohmoto M; Kawashima K; Tsunemitsu H; Eguchi M
    Vet Microbiol; 2005 Feb; 105(3-4):301-5. PubMed ID: 15708828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses.
    Bohach GA; Fast DJ; Nelson RD; Schlievert PM
    Crit Rev Microbiol; 1990; 17(4):251-72. PubMed ID: 2206394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency of superantigen encoding genes of Staphylococcus aureus isolates collected from multiple sclerosis (MS) patients and nasal carriers.
    Sadeghi J; Alizadeh N; Ahangar Oskouei M; Laghusi D; Savadi Oskouei D; Nikanfar M; Seyyed Mousavi MN
    Microb Pathog; 2019 Feb; 127():316-319. PubMed ID: 30553909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probable enterotoxin-associated toxic shock syndrome caused by Staphylococcus epidermidis.
    Pomputius WF; Kilgore SH; Schlievert PM
    BMC Pediatr; 2023 Mar; 23(1):108. PubMed ID: 36882717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the mechanism of action of the exfoliative toxins of Staphylococcus aureus.
    Ladhani S
    FEMS Immunol Med Microbiol; 2003 Nov; 39(2):181-9. PubMed ID: 14625102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Isolation and purification of biologically active substances from Staphylococcus aureus isolated from a skin disease. II. Isolation and purification of exfoliative toxin].
    Sugai M
    Hiroshima Daigaku Shigaku Zasshi; 1987 Dec; 19(2):402-8. PubMed ID: 3504874
    [No Abstract]   [Full Text] [Related]  

  • 37. [Gram-positive septic-toxic shock with bullae. Intraepidermal splitting as an indication of toxin effect].
    Buslau M; Biermann H; Shah PM
    Hautarzt; 1996 Oct; 47(10):783-9. PubMed ID: 9036130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Causative agent of impetigo: staphylococcal exfoliative toxin and regulation of the toxin production in Staphylococcus aureus].
    Sakurai S
    Nihon Saikingaku Zasshi; 1996 Aug; 51(3):813-22. PubMed ID: 8840812
    [No Abstract]   [Full Text] [Related]  

  • 39. Multiplex PCR for detection of genes for Staphylococcus aureus enterotoxins, exfoliative toxins, toxic shock syndrome toxin 1, and methicillin resistance.
    Mehrotra M; Wang G; Johnson WM
    J Clin Microbiol; 2000 Mar; 38(3):1032-5. PubMed ID: 10698991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Staphylococcus aureus express unique superantigens depending on the tissue source.
    Banks MC; Kamel NS; Zabriskie JB; Larone DH; Ursea D; Posnett DN
    J Infect Dis; 2003 Jan; 187(1):77-86. PubMed ID: 12508149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.